i-base

Annual report and accounts

HIV i-Base accounts and funding for 2016/17

i-Base would like to thank all funders for their continued support, without which our work would not have been possible.

CATEGORIES OF EXPENDITURE AMOUNT (£) DESCRIPTION
Fundraising costs 10,014
Publications
138,016
HTB, patient guides and forms, foreign translations
Phone line/information officer 47,556 Phone line services, email Q&A, information requests
Website
11,026
Maintenance, online publications, historical database
UK CAB 44,672 UK Community Advisory Board quarterly meetings
Community outreach 4,736 Work with community organisations in the UK
Community outreach overseas 94,175 Work with community organisations abroad
Research and other partnerships 72,864 Patient representation and research partnerships
External conferences
29,939
Attendance at medical and other conferences
AfroCAB 42,987 Secretariat services for AfroCab African community advocates
Management and administration 26,189 Including additional costs related to relocation
Governance costs
9,570
Total
522,174

Major funders 2016/17

Only grants of £1,000 or over are listed separately.

ORGANISATION AMOUNT (£) PROJECT TO WHICH FUNDS ALLOCATED
Charitable bodies and organisations, private donations and other income
The Monument Trust 200,000 Treatment Information, HTB, HTB South, publications, website, work in Southern Africa.
MAC AIDS Foundation 29,000 Treatment publications
University College Hospital 13,088 Research collaboration
Publisher’s licensing 2,988 Copyright fees
ITPC 2,200 Research partnerships
Brighton & Sussex University Hospital 7,868 Research collaboration (SUPA)
University of Minnesotta  11,578 Research collaboration
UNITAID 46,225 Research project
USAID 124,197 Research project
PENTA/WHO 17,591 Research project
FOSI 19,657 Research project
Other small grants and income 12,170 Small grants, advisory honoraria, bank interest etc
Sub-total 466,562
Pharmaceutical industry
Merck Sharpe & Dohme (MSD)
3,000
UK-CAB
Gilead Sciences Limited
11,500
Treatment information, core funding and UK-CAB
Bristol-Myers Squibb (BMS)
3,000
UK-CAB
ViiV Healthcare 19,283 Treatment information service and UK-CAB
Sub-total 36,783
Charitable and Pharmaceutical Industry support received on behalf of AfroCAB
Janssen 33,382
Sub Total income received on behalf of AfroCAB 33,382
Total income for the year
591,832

Annual summary accounts (PDF files)

Year ended 31 March 2017 (950 Kb)

Year ended 31 March 2016 (880 Kb)

Year ended 31 March 2015 (700 Kb)

Year ended 31 March 2014 (680 Kb)

Year ended 31 March 2013 (640 Kb)

Year ended 31 March 2012 (640 Kb)

Year ended 31 March 2011 (590 Kb)

Year ended 31 March 2010 (700 Kb)

Year ended 31 March 2009 (1.7 MB)

Year ended 31 March 2008 (686 Kb)

Year ended 31 March 2007 (60 Kb)

Year ended 31 March 2006 (56 Kb)

Year ended 31 March 2005 (48 Kb)

Year ended 31 March 2004 (40 Kb)

Year ended 31 March 2003 (36 Kb)

Year ended 31 March 2002 (40 Kb)

Last updated: 20 January 2018.